Edition:
United Kingdom

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
5:02pm BST
Change (% chg)

$0.01 (+1.68%)
Prev Close
$0.60
Open
$0.66
Day's High
$0.68
Day's Low
$0.60
Volume
254,844
Avg. Vol
66,932
52-wk High
$2.83
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT).  Full Article

Onconova Says Moving Forward With Pivotal Late-Stage Trial
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS.ONCONOVA - DMC RECOMMENDS CONTINUATION OF INSPIRE TRIAL WITH TRIAL EXPANSION PER ADAPTIVE DESIGN BASED ON INTERIM ANALYSIS RESULTS FOR OS.ONCONOVA - TRIAL EXECUTIVE COMMITTEE UNANIMOUSLY AGREED TO CONTINUE INTENT TO TREAT STUDY POPULATION, INCREASE CLINICAL TRIAL ENROLLMENT.ONCONOVA - EXPANDED INSPIRE STUDY WILL INCREASE ENROLLMENT BY ADDING 135 PATIENTS TO ORIGINAL TARGET, TO REACH TOTAL ENROLLMENT OF 360 PATIENTS.  Full Article

Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE.ONCONOVA THERAPEUTICS - UNDER TERMS, NCI WILL CONDUCT RESEARCH ON RIGOSERTIB IN PEDIATRIC CANCER ASSOCIATED RASOPATHIES.  Full Article

Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5.ONCONOVA THERAPEUTICS INC - HANX WILL FUND STUDIES TOWARDS INVESTIGATIONAL NEW DRUG APPLICATIONS IN BOTH U.S. AND CHINA.ONCONOVA THERAPEUTICS INC - AGREEMENT INCLUDES LICENSING FEE, CUSTOMARY MILESTONE PAYMENTS AND ROYALTIES ON SALES OF ON 123300.ONCONOVA THERAPEUTICS INC - HANX TO COMMERCIALIZE ON 123300 IN GREATER CHINA, ONCONOVA RETAINS RIGHTS IN REST OF WORLD.  Full Article

Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​.  Full Article

Onconova Therapeutics prices public offering
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics announces pricing of public offering of common stock.Agreed to sell approximately 920,000 shares of its common stock for gross proceeds of approximately $1.38 million​.Each share of common stock is being sold at a price of $1.50 per share​.  Full Article

Onconova Therapeutics reports Q3 revenue $100,000
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results.Q3 revenue $100,000 versus $1.7 million.Q3 revenue view $152,000 -- Thomson Reuters I/B/E/S.Onconova Therapeutics Inc - Qtrly loss per share $0.71.  Full Article

Onconova Therapeutics announces plan of termination to reduce a number of positions
Tuesday, 30 Aug 2016 

Onconova Therapeutics : On August 30, communicated to certain employees its plan of termination to reduce a number of positions effective as of August 30 . Estimates net reduction to be about 6 employees, which represents about 21 percent of its workforce - SEC filing .As a result of workforce reduction, estimates will have annual net savings of about $1.4 million.  Full Article

Premkumar Reddy reports a stake of 5.8 pct in Onconova Therapeutics
Friday, 19 Aug 2016 

:Premkumar Reddy reports a stake of 5.8 pct in Onconova Therapeutics Inc as of July 29, 2016 - SEC Filing.  Full Article

Tyndall Capital reports 13.5 percent passive stake in Onconova
Thursday, 18 Aug 2016 

Onconova Therapeutics Inc :Tyndall Capital Partners LP reports 13.5 percent passive stake in Onconova Therapeutics Inc, as of July 29, 2016 - SEC filing.  Full Article

BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting

* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING